A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/11/2004	WO2004096130A2 Inhibitors of akt activity
11/11/2004	WO2004096129A2 Inhibitors of akt activity
11/11/2004	WO2004096128A2 Hiv integrase inhibitors
11/11/2004	WO2004096125A2 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
11/11/2004	WO2004096122A2 Use of ngf antagonists and opioids for treating pain
11/11/2004	WO2004096118A2 Composition for improving cognition and memory
11/11/2004	WO2004096116A2 Diazabicyclononene derivatives
11/11/2004	WO2004095942A2 Caffeinated tablet
11/11/2004	WO2004087053A9 Dipeptidyl peptidase inhibitors
11/11/2004	WO2004084831A3 Optimized expression of hpv 31 l1 in yeast
11/11/2004	WO2004082579A3 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
11/11/2004	WO2004080482A3 Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
11/11/2004	WO2004078748A3 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
11/11/2004	WO2004078138A3 Prophylactic treatment of uv-induced epidermal neoplasia
11/11/2004	WO2004078133A3 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor
11/11/2004	WO2004076011A3 System and method for facilitating play of a game with user-selected elements
11/11/2004	WO2004075864A3 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
11/11/2004	WO2004075853A9 Halogenated triptolide derivatives as immunomodulators and anticancer agents
11/11/2004	WO2004075825A3 Dosage forms of amlodipine and processes for their preparation
11/11/2004	WO2004074266A8 Hiv inhibiting 1,2,4-triazines
11/11/2004	WO2004073699A8 Pharmaceuticals comprising shikonins as active constituent
11/11/2004	WO2004073684A3 Lipophilic drug delivery vehicle and methods of use thereof
11/11/2004	WO2004073614A3 Combination therapy for the treatment of immunoinflammatory disorders
11/11/2004	WO2004073597A3 Bioadhesive liquid composition which is substancially free of water
11/11/2004	WO2004069240A3 Use in therapy of endocannabinoid-like compounds
11/11/2004	WO2004069224A3 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
11/11/2004	WO2004069209A3 Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis
11/11/2004	WO2004066963A3 N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
11/11/2004	WO2004066920A3 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
11/11/2004	WO2004064726A3 Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
11/11/2004	WO2004058168B1 METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
11/11/2004	WO2004056745A3 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors
11/11/2004	WO2004056306A3 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
11/11/2004	WO2004056305A3 Administration of capsaicinoids
11/11/2004	WO2004054511A3 Analgesic combination comprising nalbuphine
11/11/2004	WO2004053097A3 Chemopreventive and therapeutic aspects of polyphenolic compositions and assays
11/11/2004	WO2004045539A3 Anti-microbial agents derived from methionine sulfoximine analogues
11/11/2004	WO2004044219A3 Xanthene compounds for cancer chemotherapy
11/11/2004	WO2004043337A3 Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
11/11/2004	WO2004041214A3 Methods for treating migraine
11/11/2004	WO2004039325A3 Treatment of pain with jnk inhibitors
11/11/2004	WO2004038001A3 Substituted tetracycline compounds for the treatment of malaria
11/11/2004	WO2004038000A3 Methods of using substituted tetracycline compounds to modulate rna
11/11/2004	WO2004035021A3 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
11/11/2004	WO2004032903A3 Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier
11/11/2004	WO2004032872A3 Epo D + 5-FU/GEMCITABINE
11/11/2004	WO2004028516A3 Compositions for the inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
11/11/2004	WO2004026844A9 Methods and compositions of novel triazine compounds
11/11/2004	WO2004026295A3 Use of skin-protecting substances
11/11/2004	WO2004024096A3 Method of treating tremors
11/11/2004	WO2004017917A3 Method for the prevention and/or treatment of atherosclerosis
11/11/2004	WO2004014849A3 Isosorbide mononitrate compositions and methods of their use
11/11/2004	WO2004012654A3 Oligonucleotides for treating proliferative disorders
11/11/2004	WO2004011625A3 Polymorphisms for predicting disease and treatment outcome
11/11/2004	WO2003101380A3 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
11/11/2004	WO2003097356A9 Camptothecin derivatives and polymeric conjugates thereof
11/11/2004	WO2003087411A8 Method to inhibit cell growth using oligonucleotides
11/11/2004	WO2003079973A3 Mitotic kinesin inhibitors
11/11/2004	WO2003077850A3 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
11/11/2004	WO2003072066A3 Compositions and methods for the treatment of glaucoma and ocular hypertension
11/11/2004	WO2003059258A3 Compositions and methods for treating heart failure
11/11/2004	WO2003050085A8 CRYSTALLINE [R-(R,R)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1)
11/11/2004	WO2003029220A3 Preparation of an anhydrous quinoline-based cetp inhibitor by crystallization
11/11/2004	WO2000063175A3 Novel process
11/11/2004	US20040225140 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
11/11/2004	US20040225139 a 3-oxo-androstrane carbothioic acid compound
11/11/2004	US20040225132 Carvedilol
11/11/2004	US20040225130 Imidazolyl derivatives as corticotropin releasing factor inhibitors
11/11/2004	US20040225123 Substituted phenyl naphthalenes as estrogenic agents
11/11/2004	US20040225111 Therapy for osteoporosis
11/11/2004	US20040225110 Method for enhancing integrity of epithelium using retinoic acid
11/11/2004	US20040225022 Propofol formulation containing reduced oil and surfactants
11/11/2004	US20040225021 Polyamine compounds and compositions for use in conjunction with cancer therapy
11/11/2004	US20040225020 optically pure (-)-bupropion is effective in aiding or achieving smoking cessation while avoiding adverse effects associated with the administration of racemic bupropion.
11/11/2004	US20040225019 administering to a subject an effective amount of a halogenated pheniramine (chlorpheniramine or brompheniramine) to decrease the signs or symptoms of motion sickness orally or topically
11/11/2004	US20040225018 administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal
11/11/2004	US20040225017 Chloramine T based teat cleaner and related process
11/11/2004	US20040225016 administering bis[thio-hydrazide amide] Compounds for treating multi-drug resistant cancer
11/11/2004	US20040225014 administration of a topical ophthalmic formulation containing as an active ingredient a 15-keto-prostaglandin compound having a ring structure at the end of omega chain, possessed less hair growth activity
11/11/2004	US20040225013 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
11/11/2004	US20040225011 E.g., ajulemic acid; used for decreasing cell proliferation
11/11/2004	US20040225010 Method for decreasing cholesterol level in blood
11/11/2004	US20040225009 For orally administered antitumor agents
11/11/2004	US20040225008 such as N-(4-{[methyl-(2-propynyl)amino]methyl}phenyl)-2-thiophenecarboximidamine; for inhibiting nitrogen oxide synthases and/or monoamine oxidases
11/11/2004	US20040225006 Useful in treatment and prophylaxis of conditions mediated by s-CD23 or tumor necrosis factor; autoimmune disease, inflammation, allergy
11/11/2004	US20040225005 substituted with p-chlorobenzene and a pyrrolethoxybenzene; antitumor
11/11/2004	US20040225004 Administering diindolylymethane (DIM and related indole derivatives include combinations with deferoxamine, deferiprone, bipyridyl, Desferri-exochelin, picolinic acid, 3-hydroxypicolinic acid, and sodium butyrate as iron/zinc chelators for treating papillomavirus infections
11/11/2004	US20040225003 4,6-Dimethyl-3-{[3'-(N,N-dimethylaminomethyl)-4-hydroxy-4'-(3''-methoxyphenyl)-cyclohexylamino]-methyl}-1H-indole 2-carboxylic acid ethyl ester or other derivatives of substituted indoles; for treatment or prevention of neurodegenerative diseases, psychological disorders, AIDS, inflammation or allergies
11/11/2004	US20040225002 Derivatives of isoindigo, indigo and indirubin and methods of treating cancer
11/11/2004	US20040225001 Imidazolyl derivatives as corticotropin releasing factor inhibitors
11/11/2004	US20040224999 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
11/11/2004	US20040224998 Losartan potassium synthesis
11/11/2004	US20040224996 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/11/2004	US20040224995 6-hydroxy-1-benzopyran derivative or phenolic derivative for treating acute neurodegenerative disorders characterized by toxic levels of hydrogen peroxide, or toxic levels of glutamate
11/11/2004	US20040224993 Diphenylurea compounds
11/11/2004	US20040224992 Antiinflammatory agents; antiallergens; antiproliferative agents; 4-(5-Fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentanoic acid (3,5-dichloro-phenyl)-amide
11/11/2004	US20040224991 Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
11/11/2004	US20040224989 S-lansoprazole compositions and methods
11/11/2004	US20040224988 Administering 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole as dosage form to treat cancer
11/11/2004	US20040224986 Piperidinyl targeting compounds that selectively bind integrins

1 ... 4894 4895 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 ... 7860